



**Publication of Annual Report**

June 27, 2024 1:34 PM EDT

RNS Number : 2055U  
MaxCyte, Inc.  
27 June 2024



## Publication of Annual Report

**ROCKVILLE, MD, June 27, 2024** - MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovative, cell-based research, announces that it has published its Annual Report and Accounts for the year ending 31 December 2023.

The Annual Report is available to view on the Company's website at <https://investors.maxcyte.com/> and printed copies of the reports have been posted to those shareholders who have elected to continue to receive paper communications.

### About MaxCyte

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical, and regulatory support, we aim to guide them on their journey to transform human health. Learn more at [maxcyte.com](https://maxcyte.com) and follow us on [Twitter](#) and [LinkedIn](#).

### MaxCyte Contacts:

#### *US IR Adviser*

##### **Gilmartin Group**

David Deuchler, CFA

+1 415-937-5400

[ir@maxcyte.com](mailto:ir@maxcyte.com)

#### *Nominated Adviser and Joint*

##### **Corporate Broker**

Panmure Gordon

Emma Earl / Freddy Crossley

Corporate Broking

Rupert Dearden

+44 (0)20 7886 2500

#### *UK IR Adviser*

##### **ICR Consilium**

Mary-Jane Elliott

Chris Welsh

+44 (0)203 709 5700

[maxcyte@consilium-comms.com](mailto:maxcyte@consilium-comms.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For

further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

ACSUBOORSOUNUAR